Physician profile
Daniel Mark Payne
NPI 1952861288
$1,153.97
in general payments reported to CMS, 2019-2025
30 companies · $668 in 2025
The $668 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $108 · 2024: $378 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.28 | 2024-2025 | |
| Viiv Healthcare Company | $104.74 | 2025 | Apretude |
| Lilly USA, LLC | $88.13 | 2023-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $69.42 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Astellas Pharma US INC | $61.36 | 2025 | Veozah |
| Gilead Sciences, INC. | $55.73 | 2024-2025 | |
| Dynavax Technologies Corporation | $42.62 | 2023-2025 | Heplisav-B |
| Corium, LLC | $41.19 | 2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.38 | 2024-2025 | Jardiance |
| Nevro Corp. | $34.02 | 2024 | Senza |
| Inspire Medical Systems, INC. | $32.69 | 2025 | Inspire |
| Pfizer INC. | $30.97 | 2025 | |
| Merck Sharp & Dohme LLC | $30.89 | 2024-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Globus Medical, INC. | $29.82 | 2025 | Senza |
| Radius Health, INC. | $21.00 | 2025 | Tymlos |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.83 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.72 | 2025 | Voquezna |
| Corcept Therapeutics | $18.68 | 2025 | Korlym |
| Treace Medical Concepts, INC. | $18.59 | 2024 | |
| Amneal Pharmaceuticals LLC | $16.79 | 2025 | Brekiya |
| Sonex Health, INC. | $16.64 | 2025 | Sx-One Microknife |
| Novo Nordisk INC | $15.15 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $14.92 | 2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Medtronic, INC. | $14.12 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $14.08 | 2023 | Spravato |
| Sanofi-Aventis U.S. LLC | $13.83 | 2025 | |
| Amgen INC. | $13.63 | 2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $12.96 | 2023 | Auvelity |
| Organon LLC | $11.11 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.